AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lantern Pharma Announces Positive LP-184 Phase 1a Results, Advancing Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
ByAinvest
Wednesday, Dec 3, 2025 8:36 am ET1min read
Lantern Pharma reported positive Phase 1a results for LP-184, a biomarker-activated cancer drug-candidate, demonstrating durable disease control in heavily pre-treated advanced cancer patients. The drug met all primary endpoints for safety and tolerability, with a 54% disease control rate at or above therapeutic dose levels. Multiple Phase 1b/2 clinical trials are now planned across cancer indications, supported by FDA designations. The company estimates the aggregate annual market opportunity for LP-184 could exceed $10 billion.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet